GlcNAcβ1-3GalNAcα1-serine/threonine is the structure of O-glycan core 3, and this process is catalyzed by β1,3-N-acetylglucosaminyltransferase 6 (β3GnT6). Core 3 structures are found only in the mucins of some tissues, such as the stomach, colon, and small intestine. β3GnT6 is a key enzyme involved in a variety of biological processes and disease development, including cell signaling, blood clot formation, and tumor progression. Anti-β3GnT6 drugs or antibodies selectively interfere with or inhibit the functions of the β3GnT6 enzyme, thereby affecting its catalytic reaction and possibly affecting related biological processes. CD BioGlyco provides efficient core 3 inhibitor development service. We have generated anti-β3GnT6 antibodies that inhibit or modulate the activity of the β3GnT6 enzyme. Below are the types of services we offer.
CD BioGlyco provides mature β3GnT6 gene synthesis and cloning service, and we will customize the target gene sequence according to client needs.
CD BioGlyco establishes cell lines suitable for expressing β3GnT6, including stable transfection, screening, and amplification of highly expressing cell lines.
CD BioGlyco cultures the cells transfected with the β3GnT6 gene in an appropriate culture medium to provide the required nutrients and conditions to support cell growth and target protein expression. Through cell culture and expansion, it produces high expression levels of β3GnT6 protein.
CD BioGlyco uses expression systems (such as eukaryotic cells, bacteria, or yeast) to express β3GnT6 protein, and purifies β3GnT6 protein through a series of separation and purification methods (such as affinity chromatography, gel filtration, ion exchange chromatography, etc.).
CD BioGlyco injects purified β3GnT6 protein into appropriate animals (such as mice) to trigger an immune response. The antibodies produced by the animals are collected and purified through affinity chromatography and other steps to obtain anti-β3GnT6 antibodies.
Fig.1 Core 3 inhibitor development service. (CD BioGlyco)
Technology: Flow cytometry
Journal: Proceedings of the National Academy of Sciences
Results: The authors developed an anti-β3GnT6 monoclonal antibody (G8-144) to study the expression profile of β3GnT6 in gastrointestinal tissues. The G8-144 mAb recognized β3GnT6 but not any other β3GnT. In a normal colon, β3GnT6 was detectable in the Golgi region of epithelial cells (Panels B and D), but not in cancer samples (Panels E and F), thus indicating that downregulation of core 3 synthase in colon cancer had the potential to inhibit cancer cell metastasis.
Fig.2 Representative staining pattern of β3GnT6. (Iwai, et al., 2005)
CD BioGlyco has a professional research team and research solutions, especially in the research and development of core 3 inhibitors. We provide a custom core 3 inhibitor development service to ensure the best development strategy. Please feel free to contact us promptly if you would like to know the development process and details.